Black Rock Inc. Brainstorm Cell Therapeutics Inc. Transaction History

Black Rock Inc.

$4.23 Trillion
Q1 2024

A detailed history of Black Rock Inc. transactions in Brainstorm Cell Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 489,313 shares of BCLI stock, worth $190,832. This represents 0.0% of its overall portfolio holdings.

Number of Shares

489,313

Previous 466,355 4.92%

Holding current value

$190,832

Previous $125,000 119.2%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.28 - $0.66 $6,428 - $15,152	22,958 Added 4.92%	489,313 $274,000
Q4 2023 Feb 13, 2024	SELL	$0.15 - $0.4 $158 - $422	-1,056 Reduced 0.23%	466,355 $125,000
Q3 2023 Nov 13, 2023	SELL	$0.2 - $2.08 $3,610 - $37,550	-18,053 Reduced 3.72%	467,411 $93,000
Q2 2023 Aug 11, 2023	BUY	$2.0 - $3.2 $22,744 - $36,390	11,372 Added 2.4%	485,464 $1 Million
Q1 2023 May 12, 2023	BUY	$1.43 - $3.3 $3,317 - $7,656	2,320 Added 0.49%	474,092 $1.56 Million

Q4 2022 Feb 13, 2023	BUY	$1.37 - $3.39 $4,729 - $11,702	3,452 Added 0.74%	471,772 $773,000
Q3 2022 Nov 14, 2022	SELL	$2.55 - $4.3 $13,803 - $23,275	-5,413 Reduced 1.14%	468,320 $2.07 Million
Q2 2022 Aug 12, 2022	SELL	$2.71 - $3.6 $2,105 - $2,797	-777 Reduced 0.16%	473,733 $1.31 Million
Q1 2022 May 12, 2022	BUY	$2.92 - $4.19 $5,939 - $8,522	2,034 Added 0.43%	474,510 $1.59 Million
Q4 2021 Feb 10, 2022	BUY	$2.81 - $4.23 $9,860 - $14,843	3,509 Added 0.75%	472,476 $1.89 Million
Q3 2021 Nov 09, 2021	SELL	$3.14 - $4.09 $16,893 - $22,004	-5,380 Reduced 1.13%	468,967 $1.55 Million
Q2 2021 Aug 11, 2021	BUY	$3.01 - $4.01 $1.43 Million - $1.9 Million	474,347 New	474,347 $1.8 Million

Others Institutions Holding BCLI

# of Institutions

Shares Held

4.09M

Call Options Held

63.2K

Put Options Held

800

View Full List

About BRAINSTORM CELL THERAPEUTICS INC.

Ticker BCLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,486,200
Market Cap $14.2M
Description
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...

More about BCLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account